Importance of early diagnosis of Sjögren syndrome

doi:10.16138/j.1673-6087.2024.06.12

Abstract

Abstract:

There are several challenges in the early diagnosis of Sjögren syndrome (SS), such as prominent glandular dysfunction in patients to make long diagnostic delays. These challenges are mainly attributed to the lack of adequate understanding of the early-stage characteristic of SS. Clinical and experimental studies have shown that early diagnosis and intervention in SS can help delay disease progression and reduce the risk of complications. To achieve early diagnosis and treatment of SS, it’s necessary to identify more useful biomarkers for the early stages of SS, and to identify high-risk people for SS through appropriate screening.

Key words: Sjögren syndrome, Early diagnosis, Epidemiology

CLC Number:

R593

FAN Kaijian, LIU Jinyu, ZHAO Futao. Importance of early diagnosis of Sjögren syndrome[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(06): 417-421.

References 52

[1]	Vasaitis L, Nordmark G, Theander E, et al. Population-based study of patients with primary Sjögren’s syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences[J]. Scand J Rheumatol, 2020, 49(3):225-232. doi: 10.1080/03009742.2019.1696403 pmid: 32153241
[2]	Mariette X, Criswell LA. Primary Sjögren’s syndrome[J]. N Engl J Med, 2018, 378(10):931-939.
[3]	Brito-Zerón P, Acar-Denizli N, Ng WF, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome[J]. Rheumatology (Oxford), 2020, 59(9):2350-2359. doi: 10.1093/rheumatology/kez578 pmid: 31873754
[4]	Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome[J]. Arthritis Rheumatol, 2017, 69(1):35-45.
[5]	Mofors J, Arkema EV, Björk A, et al. Infections increase the risk of developing Sjögren’s syndrome[J]. J Intern Med, 2019, 85(6):670-680.
[6]	Beydon M, McCoy S, Nguyen Y, et al. Epidemiology of Sjögren syndrome[J]. Nat Rev Rheumatol, 2024, 20(3):158-169.
[7]	Chen H, McCann P, Lien T, et al. Prevalence of dry eye and Meibomian gland dysfunction in Central and South America: a systematic review and meta-analysis[J]. BMC Ophthalmol, 2024, 24(1):50. doi: 10.1186/s12886-023-03249-w pmid: 38297204
[8]	Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS Ⅱ epidemiology report[J]. Ocul Surf, 2017, 15(3):334-365. doi: S1542-0124(17)30109-X pmid: 28736337
[9]	Retamozo S, Acar-Denizli N, Horváth IF, et al. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome[J]. Clin Exp Rheumatol, 2021, 39 Suppl 133(6):166-174. doi: 10.55563/clinexprheumatol/egnd1i pmid: 34919044
[10]	Wu R, Chen Z, Yu J, et al. A graph-learning based model for automatic diagnosis of Sjögren’s syndrome on digital pathological images: a multicentre cohort study[J]. J Transl Med, 2024, 22(1):748.
[11]	Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients[J]. Ann Rheum Dis, 2017, 76(6):1042-1050. doi: 10.1136/annrheumdis-2016-209952 pmid: 27899373
[12]	Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren’s syndrome[J]. Eur Respir Rev, 2016, 25(140):110-123. doi: 10.1183/16000617.0011-2016 pmid: 27246587
[13]	Ramírez Sepúlveda JI, Kvarnström M, Brauner S, et al. Difference in clinical presentation between women and men in incident primary Sjögren’s syndrome[J]. Biol Sex Differ, 2017, 8:16. doi: 10.1186/s13293-017-0137-7 pmid: 28507729
[14]	Wei L, Zhifei X, Xiaoran N, et al. Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles[J]. Rheumatology (Oxford), 2022, 61(2):597-605.
[15]	Goules AV, Argyropoulou OD, Pezoulas VC, et al. Primary Sjögren’s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development[J]. Front Immunol, 2020, 11:594096.
[16]	Beydon M, Seror R, Le Guern V, et al. Impact of patient ancestry on heterogeneity of Sjögren’s disease[J]. RMD Open, 2023, 9(1):e002955.
[17]	Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren’s syndrome[J]. Rheumatology (Oxford), 2016, 55(3):450-60. doi: 10.1093/rheumatology/kev354 pmid: 26412810
[18]	Kim HJ, Kim KH, Hann HJ, et al. Incidence, mortality, and causes of death in physician-diagnosed primary Sjögren’s syndrome in Korea[J]. Semin Arthritis Rheum, 2017, 47(2):222-227.
[19]	Jin L, Dai M, Li C, et al. Risk factors for primary Sjögren’s syndrome: a systematic review and meta-analysis[J]. Clin Rheumatol, 2023, 42(2):327-338.
[20]	Mofors J, Björk A, Richardsdotter Andersson E, et al. Cigarette smoking patterns preceding primary Sjögren’s syndrome[J]. RMD Open, 2020, 6(3):e001402.
[21]	Ben-Eli H, Aframian DJ, Ben-Chetrit E, et al. Shared medical and environmental risk factors in dry eye syndrome, Sjogren’s syndrome, and B-cell non-Hodgkin lymphoma: a case-control study[J]. J Immunol Res, 2019, 2019:9060842.
[22]	Olsson P, Turesson C, Mandl T, et al. Cigarette smoking and the risk of primary Sjögren’s syndrome: a nested case control study[J]. Arthritis Res Ther, 2017, 19(1):50. doi: 10.1186/s13075-017-1255-7 pmid: 28270185
[23]	Mccoy SS, Sampene E, Baer AN. Association of Sjögren’s syndrome with reduced lifetime sex hormone exposure: a case-control study[J]. Arthritis Care Res (Hoboken), 2020, 72(9):1315-1322.
[24]	Machowicz A, Hall I, De Pablo P, et al. Mediterranean diet and risk of Sjögren’s syndrome[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4):216-221.
[25]	Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome[J]. Nat Rev Dis Primers, 2016, 2:16047. doi: 10.1038/nrdp.2016.47 pmid: 27383445
[26]	Auteri S, Alberti ML, Fernández ME, et al. Occult primary Sjögren Syndrome in patients with interstitial pneumonia with autoimmune features[J]. Respir Med, 2021, 182:106405.
[27]	Mæland E, Miyamoto ST, Hammenfors D, et al. Understanding fatigue in Sjögren’s syndrome: outcome measures, biomarkers and possible interventions[J]. Front Immunol, 2021, 12:703079.
[28]	Unger J, Mattsson M, Drăgoi RG et al. The experiences of functioning and health of patients with primary Sjögren’s syndrome[J]. Front Med (Lausanne), 2021, 8:770422.
[29]	McCoy SS, Bartels CM, Saldanha IJ, et al. National Sjögren’s foundation survey: burden of oral and systemic involvement on quality of life[J]. J Rheumatol, 2021, 48(7):1029-1036.
[30]	Tarn J, Lendrem D, McMeekin P, et al. Primary Sjögren’s syndrome: longitudinal real-world, observational data on health-related quality of life[J]. J Intern Med, 2022, 291(6):849-855.
[31]	Wicheta S, van der Groen T, Faquin WC, et al. Discrepancies in interpretation of the minor salivary gland biopsy in the diagnosis of Sjögren syndrome[J]. J Oral Maxillofac Surg, 2019, 77(8):1628-1635.
[32]	Fisher BA, Jonsson R, Daniels T, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome[J]. Ann Rheum Dis, 2017, 76(7):1161-1168.
[33]	Wicheta S, van der Groen T, Faquin WC, et al. Minor Salivary gland biopsy-an important contributor to the diagnosis of Sjögren syndrome[J]. J Oral Maxillofac Surg, 2017, 5(12):2573-2578.
[34]	Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjögren’s syndrome: promises and pitfalls[J]. Clin Exp Rheumatol, 2018, 36 Suppl 112(3):222-233. pmid: 30156550
[35]	Shiboski CH, Baer AN, Shiboski SC, et al. Natural history and predictors of progression to Sjögren’s syndrome among participants of the Sjögren’s International Collaborative Clinical Alliance Registry[J]. Arthritis Care Res (Hoboken), 2018, 70(2):284-294.
[36]	Costa S, Quintin-Roué I, Lesourd A, et al. Reliability of histopathological salivary gland biopsy assessment in Sjögren’s syndrome: a multicentre cohort study[J]. Rheumatology (Oxford), 2015, 54(6):1056-64.
[37]	Panchovska M. Questions from patients and doctors on negative minor salivary gland biopsy in Sjögren syndrome[J]. J Rheumatol, 2021, 48(1):149. doi: 10.3899/jrheum.200579 pmid: 32934133
[38]	Blokland SLM, Hillen MR, Kruize AA, et al. Increased CCL25 and T helper cells expressing CCR9 in the salivary glands of patients with primary Sjögren’s syndrome: potential new axis in lymphoid neogenesis[J]. Arthritis Rheumatol, 2017, 69(10):2038-2051.
[39]	Janga SR, Shah M, Ju Y, et al. Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjögren’s Syndrome[J]. Biomarkers, 2019, 24(1):91-102.
[40]	Berry JS, Tarn J, Casement J, et al. Examining the biological pathways underlying clinical heterogeneity in Sjogren’s syndrome: proteomic and network analysis[J]. Ann Rheum Dis, 2024, 83(1):88-95.
[41]	Delli K, Haacke EA, Kroese FG, et al. Towards personalised treatment in primary Sjögren’s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment[J]. Ann Rheum Dis, 2016, 75(11):1933-1938.
[42]	Chen CT, Tseng YC, Yang CW, et al. Increased risks of spontaneous acterial peritonitis and interstitial lung disease in primary biliary cirrhosis patients with concomitant Sjögren syndrome[J]. Medicine (Baltimore), 2016, 95(2):e2537.
[43]	Huang Y, Qiu Y, Xie Z, et al. Risk factors and prognosis of interstitial lung disease for primary Sjögren syndrome patients: a retrospective case-control study[J]. Clin Rheumatol, 2023, 42(11):3033-3041.
[44]	Al Qassimi S, Namas R. Advanced cystic lung disease secondary to Sjögren syndrome[J]. J Clin Rheumatol, 2024, 30(6):e155.
[45]	Martín-Nares E, Hernández-Molina G. Novel autoantibodies in Sjögren’s syndrome: a comprehensive review[J]. Autoimmun Rev, 2019, 18(2):192-198. doi: S1568-9972(18)30292-1 pmid: 30572138
[46]	Jin Y, Li J, Chen J, et al. Tissue-specific autoantibodies improve diagnosis of primary Sjögren’s syndrome in the early stage and indicate localized aalivary injury[J]. J Immunol Res, 2019, 2019:3642937.
[47]	He J, Jiang J, Baumgart K. Candidate autoantibodies for primary Sjögren’s syndrome: where are they now?[J]. Clin Exp Rheumatol, 2022, 40(12):2387-2394.
[48]	Longobardi S, Lopez-Davis C, Khatri B, et al. Autoantibodies identify primary Sjögren’s syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B[J]. Ann Rheum Dis, 2023, 82(9):1181-1190. doi: 10.1136/ard-2022-223105 pmid: 37147113
[49]	杨玉淑, 齐晅, 丁萌, 等. 抗唾液腺蛋白1抗体联合抗腮腺分泌蛋白抗体对干燥综合征的诊断价值[J]. 北京大学学报(医学版), 2024, 56(5):845-852.
[50]	Tan PH, Ji J, Hsing CH, et al. Emerging roles of Type-I interferons in neuroinflammation, neurological diseases, and long-haul COVID[J]. Int J Mol Sci, 2022, 23(22):14394.
[51]	Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J]. Rheumatology (Oxford), 2024, 63(3):698-705.
[52]	Huang H. A study of CD19/BCMA chimeric antigen receptor T cells therapy for patients with refractory Sjogren’s syndrome[EB/OL]. 2021. https://clinicaltrials.gov/ct2/show/NCT05085431